EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Aldosterone synthase inhibitors may alter how primary care treats hypertension

Peter J Lin iD

American Journal of Hypertension · 2026

DOI: 10.1093/ajh/hpag093 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hypertension, 2026. Verfasst von Peter J Lin. Beteiligte Einrichtung: Canadian Heart Research Centre, 398 Steeles Avenue West, Units #11-14, Thornhill, Ontario, L4J 6X3, Canada. Hauptthemen laut MEDLINE: Hypertension, Cytochrome P-450 CYP11B2, Hyperaldosteronism, Antihypertensive Agents. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertension guidelines recommend adding antihypertensive therapies until the blood pressure (BP) is below a specific target. If the BP is not below target with 3 medications, including a diuretic, then it is labeled resistant hypertension, and then we investigate for secondary causes, such as primary aldosteronism (PA). PA testing seems complex with 3 results: aldosterone, renin, and the aldosterone-renin ratio. Hence, these tests are ordered infrequently, and the diagnosis of PA is often delayed or never made. Also, heart failure, chronic kidney disease, and other conditions can have elevated aldosterone, which are not PA-related. The traditional treatment with aldosterone receptor blockers/mineralocorticoid receptor antagonists has been helpful, but they block the effects that are mediated through the mineralocorticoid receptor. The non-receptor effects of high aldosterone may continue to cause harm. Therefore, blocking the production of aldosterone with an aldosterone synthase inhibitor (ASI) could be a more complete strategy to address elevated aldosterone levels. In addition, an “ASI Challenge” may help us decide which patients need formal testing for PA. If the systolic blood pressure drops a significant amount (>10 mm Hg), then that suggests aldosterone is a key component of the uncontrolled BP, and those patients should be considered for formal PA testing. For those who drop a modest amount (<10 mm Hg), they would be less likely to need PA testing. Such an approach could use an ASI agent as a diagnostic/screening tool as well as a therapeutic agent, which would be very helpful in the primary care setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionCytochrome P-450 CYP11B2HyperaldosteronismAntihypertensive AgentsPrimary Health CareBlood PressureEnzyme InhibitorsHumansAldosteroneMineralocorticoid Receptor AntagonistsTreatment Outcome

Stichwörter der Autor:innen

aldosteroneblood pressurehypertensionprimary careresistant hypertension

Substanzen

Cytochrome P-450 CYP11B2Antihypertensive AgentsAldosteroneMineralocorticoid Receptor AntagonistsEnzyme Inhibitors

Autor:innen und Institutionen

  • Canadian Heart Research Centre, 398 Steeles Avenue West, Units #11-14, Thornhill, Ontario, L4J 6X3, Canada.

ORCID-Profile: Peter J Lin

Zitieren

APA

Lin, P. J. (2026). Aldosterone synthase inhibitors may alter how primary care treats hypertension. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpag093

Vancouver

Lin PJ. Aldosterone synthase inhibitors may alter how primary care treats hypertension. American Journal of Hypertension. 2026. doi:10.1093/ajh/hpag093

BibTeX
@article{Lin2026,
  author = {Lin, Peter J},
  title = {Aldosterone synthase inhibitors may alter how primary care treats hypertension},
  journal = {American Journal of Hypertension},
  year = {2026},
  doi = {10.1093/ajh/hpag093}
}
Kostenlos starten →